Stocks
Nvidia-Backed AI Biotech Iambic Seeks Up to $100M in U.S. IPO
Iambic Therapeutics, an AI-driven drug discovery company backed by Nvidia, has filed for a U.S. initial public offering (IPO) on the Nasdaq under the ticker IAM.
The San Diego-based biotech plans to use the IPO proceeds and existing cash to advance three cancer drug candidates through clinical development, with the remaining funds earmarked for general corporate purposes.
Iambic's lead candidate, IAM1363, is an experimental oral HER2 inhibitor being evaluated in an early-stage Phase 1/1b trial for solid tumors. Two additional programs, IAM217 and IAM-C1, are in preclinical development.